- Featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**
Phase
3Span
Sponsor
London
Recruiting
- Featured
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase
1Span
166 weeksSponsor
Incyte CorporationLondon
Recruiting
- Featured
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase
1Span
213 weeksSponsor
Incyte CorporationLondon
Recruiting
- Featured
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Phase
1Span
128 weeksSponsor
Hoffmann-La RocheLondon
Recruiting
Hammersmith
Recruiting
Healthy Volunteers
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
This is an open-label, multicenter, global phase-2 trial evaluating the efficacy and safety of epcoritamab monotherapy and epcoritamab plus lenalidomide in elderly patients who are deemed anthracycline ineligible. The trial is designed in two stages: - Stage 1 which includes a safety run-in phase in each arm - Stage 2, an expansion of the selected treatment from Stage 1
Phase
2Span
230 weeksSponsor
GenmabFulham
Recruiting
1-6 of 6